TDMS Study 88034-06 Pathology Tables
INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) OZONE NTP Experiment-Test: 88034-06 Report: PEIRPT05 Study Type: CHRONIC 30-MONTH Date: 05/08/95 Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 22:21:59 Facility: Battelle Northwest Chemical CAS #: 10028-15-6 Lock Date: 03/09/93 Cage Range: All Reasons For Removal: All Removal Date Range: All Treatment Groups: Include All a Number of animals examined microscopically at site and number of animals with lesion Page 1 NTP Experiment-Test: 88034-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC 30-MONTH OZONE Date: 05/08/95 Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 22:21:59 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE FEMALE CONTROL 0.5 PPM 1.0 PPM ____________________________________________________________________________________________________________________________________ DISPOSITION SUMMARY Animals Initially in Study 50 50 50 Early Deaths Moribund Sacrifice 34 25 33 Natural Death 7 13 7 Survivors Terminal Sacrifice 9 12 10 Animals Examined Microscopically 50 50 50 ____________________________________________________________________________________________________________________________________ ALIMENTARY SYSTEM Gallbladder (43) (38) (44) Histiocytic Sarcoma 1 (2%) Sarcoma, Metastatic, Skin 1 (2%) Intestine Large, Cecum (45) (43) (47) Leiomyosarcoma 1 (2%) Intestine Small, Duodenum (45) (41) (46) Peyer's Patch, Histiocytic Sarcoma 1 (2%) Intestine Small, Jejunum (44) (42) (47) Intestine Small, Ileum (45) (43) (46) Carcinoma 1 (2%) Liver (49) (50) (50) Hemangiosarcoma 1 (2%) 2 (4%) Hepatocellular Carcinoma 15 (31%) 15 (30%) 6 (12%) Hepatocellular Carcinoma, Multiple 4 (8%) 3 (6%) 2 (4%) Hepatocellular Adenoma 11 (22%) 12 (24%) 9 (18%) Hepatocellular Adenoma, Multiple 2 (4%) 4 (8%) 4 (8%) Hepatocholangiocarcinoma 1 (2%) Histiocytic Sarcoma 3 (6%) 2 (4%) Osteosarcoma, Metastatic, Bone 1 (2%) Mesentery (13) (5) (10) Hemangiosarcoma 1 (20%) Histiocytic Sarcoma 1 (10%) Sarcoma, Metastatic, Skin 1 (8%) Pancreas (48) (48) (49) Histiocytic Sarcoma 1 (2%) Sarcoma, Metastatic, Skin 1 (2%) Salivary Glands (50) (48) (49) Sarcoma 1 (2%) Stomach, Forestomach (48) (50) (49) Sarcoma, Metastatic, Skin 1 (2%) Squamous Cell Papilloma 1 (2%) Stomach, Glandular (48) (49) (48) Histiocytic Sarcoma 1 (2%) Page 2 NTP Experiment-Test: 88034-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC 30-MONTH OZONE Date: 05/08/95 Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 22:21:59 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE FEMALE CONTROL 0.5 PPM 1.0 PPM ____________________________________________________________________________________________________________________________________ ALIMENTARY SYSTEM - cont Sarcoma, Metastatic, Skin 1 (2%) Tooth (1) Adamantinoma Malignant 1 (100%) ____________________________________________________________________________________________________________________________________ CARDIOVASCULAR SYSTEM Heart (50) (50) (50) Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%) ____________________________________________________________________________________________________________________________________ ENDOCRINE SYSTEM Adrenal Cortex (48) (49) (50) Adenoma 1 (2%) Histiocytic Sarcoma 1 (2%) Capsule, Adenoma 1 (2%) Adrenal Medulla (48) (49) (50) Pheochromocytoma Malignant 1 (2%) Pheochromocytoma Benign 2 (4%) 2 (4%) 1 (2%) Islets, Pancreatic (47) (47) (48) Adenoma 1 (2%) Pituitary Gland (48) (48) (49) Pars Distalis, Adenoma 19 (40%) 11 (23%) 12 (24%) Pars Distalis, Carcinoma 1 (2%) Pars Intermedia, Adenoma 1 (2%) 3 (6%) Thyroid Gland (49) (49) (50) Follicular Cell, Adenoma 1 (2%) 1 (2%) Follicular Cell, Adenoma, Multiple 2 (4%) ____________________________________________________________________________________________________________________________________ GENERAL BODY SYSTEM None ____________________________________________________________________________________________________________________________________ GENITAL SYSTEM Ovary (49) (48) (50) Cystadenoma 4 (8%) 2 (4%) 2 (4%) Granulosa Cell Tumor Benign 1 (2%) Hemangioma 1 (2%) 2 (4%) Histiocytic Sarcoma 2 (4%) 2 (4%) Luteoma 1 (2%) 1 (2%) 1 (2%) Uterus (49) (50) (50) Adenoma 1 (2%) Fibroma 1 (2%) Page 3 NTP Experiment-Test: 88034-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC 30-MONTH OZONE Date: 05/08/95 Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 22:21:59 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE FEMALE CONTROL 0.5 PPM 1.0 PPM ____________________________________________________________________________________________________________________________________ GENITAL SYSTEM - cont Hemangioma 1 (2%) 2 (4%) Hemangiosarcoma 1 (2%) Histiocytic Sarcoma 3 (6%) 1 (2%) Leiomyoma 1 (2%) Polyp Stromal 3 (6%) 2 (4%) 6 (12%) Polyp Stromal, Multiple 1 (2%) ____________________________________________________________________________________________________________________________________ HEMATOPOIETIC SYSTEM Bone Marrow (49) (49) (50) Hemangiosarcoma 1 (2%) 3 (6%) 1 (2%) Histiocytic Sarcoma 2 (4%) 1 (2%) Lymph Node (15) (6) (9) Iliac, Histiocytic Sarcoma 2 (13%) Pancreatic, Histiocytic Sarcoma 1 (7%) Renal, Histiocytic Sarcoma 1 (7%) 1 (11%) Lymph Node, Bronchial (36) (32) (33) Hepatocholangiocarcinoma, Metastatic, Liver 1 (3%) Histiocytic Sarcoma 1 (3%) 1 (3%) Lymph Node, Mandibular (38) (40) (41) Histiocytic Sarcoma 2 (5%) Lymph Node, Mesenteric (45) (48) (44) Histiocytic Sarcoma 3 (7%) 1 (2%) Lymph Node, Mediastinal (43) (36) (38) Alveolar/Bronchiolar Carcinoma, Metastatic, Lung 1 (2%) Hepatocholangiocarcinoma, Metastatic, Liver 1 (3%) Histiocytic Sarcoma 2 (5%) 1 (3%) Spleen (49) (50) (50) Hemangiosarcoma 2 (4%) 3 (6%) 3 (6%) Histiocytic Sarcoma 2 (4%) 1 (2%) Sarcoma, Metastatic, Skin 1 (2%) Thymus (35) (35) (33) Alveolar/Bronchiolar Carcinoma, Metastatic, Lung 1 (3%) ____________________________________________________________________________________________________________________________________ INTEGUMENTARY SYSTEM Mammary Gland (50) (50) (50) Adenoma 1 (2%) Carcinoma 3 (6%) 2 (4%) 2 (4%) Carcinoma, Multiple 1 (2%) Skin (50) (50) (50) Schwannoma Malignant 1 (2%) Subcutaneous Tissue, Hemangiosarcoma 1 (2%) 2 (4%) Page 4 NTP Experiment-Test: 88034-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC 30-MONTH OZONE Date: 05/08/95 Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 22:21:59 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE FEMALE CONTROL 0.5 PPM 1.0 PPM ____________________________________________________________________________________________________________________________________ INTEGUMENTARY SYSTEM - cont Subcutaneous Tissue, Histiocytic Sarcoma 1 (2%) 1 (2%) Subcutaneous Tissue, Sarcoma 1 (2%) 2 (4%) 5 (10%) Subcutaneous Tissue, Sarcoma, Multiple 1 (2%) 1 (2%) ____________________________________________________________________________________________________________________________________ MUSCULOSKELETAL SYSTEM Bone (50) (50) (50) Hemangiosarcoma 1 (2%) Osteosarcoma 2 (4%) 1 (2%) Skeletal Muscle (2) Histiocytic Sarcoma 1 (50%) Rhabdomyosarcoma 1 (50%) ____________________________________________________________________________________________________________________________________ NERVOUS SYSTEM Brain (49) (49) (50) Carcinoma, Metastatic, Harderian Gland 1 (2%) Carcinoma, Metastatic, Pituitary Gland 1 (2%) Histiocytic Sarcoma 1 (2%) ____________________________________________________________________________________________________________________________________ RESPIRATORY SYSTEM Lung (50) (49) (50) Adamantinoma Malignant, Metastatic, Tooth 1 (2%) Alveolar/Bronchiolar Adenoma 3 (6%) 3 (6%) 10 (20%) Alveolar/Bronchiolar Adenoma, Multiple 1 (2%) Alveolar/Bronchiolar Carcinoma 1 (2%) 5 (10%) 2 (4%) Alveolar/Bronchiolar Carcinoma, Multiple 2 (4%) Carcinoma, Metastatic, Harderian Gland 1 (2%) 1 (2%) Hepatocellular Carcinoma, Metastatic, Liver 2 (4%) 5 (10%) 1 (2%) Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%) Histiocytic Sarcoma 2 (4%) 2 (4%) Osteosarcoma, Metastatic, Bone 1 (2%) 1 (2%) Sarcoma, Metastatic, Skin 1 (2%) Mediastinum, Alveolar/Bronchiolar Carcinoma, Metastatic, Lung 2 (4%) Mediastinum, Hemangiosarcoma 1 (2%) Mediastinum, Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%) Mediastinum, Osteosarcoma, Metastatic, Bone 1 (2%) Mediastinum, Sarcoma, Metastatic, Skin 1 (2%) Nose (50) (49) (50) Adenoma 1 (2%) Carcinoma, Metastatic, Harderian Gland 1 (2%) Page 5 NTP Experiment-Test: 88034-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC 30-MONTH OZONE Date: 05/08/95 Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 22:21:59 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE FEMALE CONTROL 0.5 PPM 1.0 PPM ____________________________________________________________________________________________________________________________________ ____________________________________________________________________________________________________________________________________ SPECIAL SENSES SYSTEM Harderian Gland (5) (5) (3) Adenoma 4 (80%) 4 (80%) 2 (67%) Carcinoma 1 (20%) 1 (20%) 1 (33%) ____________________________________________________________________________________________________________________________________ URINARY SYSTEM Kidney (49) (49) (50) Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%) Histiocytic Sarcoma 1 (2%) 1 (2%) Urinary Bladder (47) (48) (46) Hemangioma 1 (2%) ____________________________________________________________________________________________________________________________________ SYSTEMIC LESIONS Multiple Organs *(50) *(50) *(50) Histiocytic Sarcoma 4 (8%) 3 (6%) Lymphoma Malignant 13 (26%) 12 (24%) 13 (26%) ____________________________________________________________________________________________________________________________________ * Number of animals with any tissue examined microscopically Page 6 NTP Experiment-Test: 88034-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC 30-MONTH OZONE Date: 05/08/95 Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 22:21:59 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE FEMALE CONTROL 0.5 PPM 1.0 PPM ____________________________________________________________________________________________________________________________________ TUMOR SUMMARY Total Animals with Primary Neoplasms (b) 48 49 47 Total Primary Neoplasms 115 100 105 Total Animals with Benign Neoplasms 39 32 35 Total Benign Neoplasms 62 43 59 Total Animals with Malignant Neoplasms 39 39 34 Total Malignant Neoplasms 53 57 46 Total Animals with Metastatic Neoplasms 8 10 2 Total Metastatic Neoplasm 17 17 2 Total Animals with Malignant Neoplasms Uncertain Primary Site Total Animals with Neoplasms Uncertain- Benign or Malignant Total Uncertain Neoplasms ____________________________________________________________________________________________________________________________________ a Number of animals examined microscopically at site and number of animals with lesion b Primary tumors: all tumors except metastatic tumors Page 7 NTP Experiment-Test: 88034-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC 30-MONTH OZONE Date: 05/08/95 Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 22:21:59 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE MALE CONTROL 0.5 PPM 1.0 PPM ____________________________________________________________________________________________________________________________________ DISPOSITION SUMMARY Animals Initially in Study 50 50 50 Early Deaths Natural Death 10 9 15 Moribund Sacrifice 26 30 23 Survivors Terminal Sacrifice 14 11 12 Animals Examined Microscopically 50 50 50 ____________________________________________________________________________________________________________________________________ ALIMENTARY SYSTEM Intestine Large, Cecum (44) (45) (40) Carcinoma 1 (3%) Intestine Small, Duodenum (44) (45) (38) Intestine Small, Jejunum (43) (44) (41) Carcinoma 1 (2%) 1 (2%) Sarcoma, Metastatic, Uncertain Primary Site 1 (2%) Intestine Small, Ileum (44) (45) (40) Liver (49) (50) (50) Cholangiocarcinoma 1 (2%) Hemangiosarcoma 1 (2%) Hepatocellular Carcinoma 7 (14%) 14 (28%) 14 (28%) Hepatocellular Carcinoma, Multiple 13 (27%) 3 (6%) 7 (14%) Hepatocellular Adenoma 6 (12%) 12 (24%) 11 (22%) Hepatocellular Adenoma, Multiple 7 (14%) 6 (12%) 1 (2%) Hepatocholangiocarcinoma 2 (4%) Histiocytic Sarcoma 1 (2%) 1 (2%) Sarcoma, Metastatic, Seminal Vesicle 1 (2%) Sarcoma, Metastatic, Uncertain Primary Site 1 (2%) Squamous Cell Carcinoma, Metastatic, Uncertain Primary Site 1 (2%) Squamous Cell Carcinoma, Metastatic, Stomach, Forestomach 1 (2%) Mesentery (3) (3) (4) Hemangioma 1 (33%) Hemangiosarcoma 1 (33%) Sarcoma, Metastatic, Seminal Vesicle 1 (33%) Squamous Cell Carcinoma, Metastatic, Stomach, Forestomach 1 (33%) Oral Mucosa (1) Pharyngeal, Squamous Cell Carcinoma 1 (100%) Pancreas (49) (49) (49) Squamous Cell Carcinoma, Metastatic, Stomach, Forestomach 1 (2%) Page 8 NTP Experiment-Test: 88034-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC 30-MONTH OZONE Date: 05/08/95 Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 22:21:59 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE MALE CONTROL 0.5 PPM 1.0 PPM ____________________________________________________________________________________________________________________________________ ALIMENTARY SYSTEM - cont Salivary Glands (49) (49) (50) Alveolar/Bronchiolar Carcinoma, Metastatic, Lung 1 (2%) Carcinoma 1 (2%) Stomach, Forestomach (49) (49) (50) Sarcoma, Metastatic, Seminal Vesicle 1 (2%) Squamous Cell Carcinoma 1 (2%) Squamous Cell Papilloma 2 (4%) 1 (2%) Stomach, Glandular (49) (47) (48) Sarcoma, Metastatic, Seminal Vesicle 1 (2%) Tooth (1) Odontoma 1 (100%) ____________________________________________________________________________________________________________________________________ CARDIOVASCULAR SYSTEM Heart (50) (50) (50) Alveolar/Bronchiolar Carcinoma, Metastatic, Lung 1 (2%) ____________________________________________________________________________________________________________________________________ ENDOCRINE SYSTEM Adrenal Cortex (47) (49) (49) Adenoma 2 (4%) 1 (2%) 1 (2%) Hepatocellular Carcinoma, Metastatic, Liver 1 (2%) Sarcoma, Metastatic, Seminal Vesicle 1 (2%) Adrenal Medulla (48) (48) (49) Pheochromocytoma Benign 1 (2%) Sarcoma, Metastatic, Seminal Vesicle 1 (2%) Islets, Pancreatic (49) (49) (49) Adenoma 1 (2%) Pituitary Gland (47) (49) (48) Alveolar/Bronchiolar Carcinoma, Metastatic, Lung 1 (2%) Pars Distalis, Adenoma 1 (2%) Pars Intermedia, Adenoma 2 (4%) Thyroid Gland (49) (48) (50) Follicular Cell, Adenoma 1 (2%) Follicular Cell, Carcinoma 1 (2%) ____________________________________________________________________________________________________________________________________ GENERAL BODY SYSTEM None ____________________________________________________________________________________________________________________________________ Page 9 NTP Experiment-Test: 88034-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC 30-MONTH OZONE Date: 05/08/95 Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 22:21:59 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE MALE CONTROL 0.5 PPM 1.0 PPM ____________________________________________________________________________________________________________________________________ GENITAL SYSTEM Epididymis (49) (49) (50) Histiocytic Sarcoma 1 (2%) 1 (2%) 1 (2%) Sarcoma 1 (2%) Preputial Gland (49) (49) (49) Adenoma 1 (2%) Histiocytic Sarcoma 1 (2%) Sarcoma 1 (2%) Prostate (48) (47) (47) Seminal Vesicle (48) (49) (49) Sarcoma 1 (2%) Testes (50) (49) (50) Histiocytic Sarcoma 1 (2%) Interstitial Cell, Adenoma 2 (4%) 1 (2%) 2 (4%) ____________________________________________________________________________________________________________________________________ HEMATOPOIETIC SYSTEM Bone Marrow (49) (49) (50) Alveolar/Bronchiolar Carcinoma, Metastatic, Lung 1 (2%) Hemangiosarcoma 1 (2%) 2 (4%) 2 (4%) Histiocytic Sarcoma 1 (2%) Femoral, Mast Cell Tumor NOS 1 (2%) Lymph Node (2) (3) (7) Lymph Node, Bronchial (26) (27) (32) Sarcoma, Metastatic, Uncertain Primary Site 1 (3%) Lymph Node, Mandibular (34) (31) (32) Lymph Node, Mesenteric (48) (46) (44) Histiocytic Sarcoma 1 (2%) Sarcoma, Metastatic, Uncertain Primary Site 1 (2%) Lymph Node, Mediastinal (37) (39) (43) Carcinoma, Metastatic, Harderian Gland 1 (2%) Spleen (49) (49) (50) Hemangiosarcoma 1 (2%) 3 (6%) 4 (8%) Mast Cell Tumor NOS 1 (2%) Thymus (29) (26) (25) ____________________________________________________________________________________________________________________________________ INTEGUMENTARY SYSTEM Skin (49) (50) (50) Hemangiosarcoma 1 (2%) Subcutaneous Tissue, Hemangiosarcoma 1 (2%) 2 (4%) Subcutaneous Tissue, Sarcoma 2 (4%) ____________________________________________________________________________________________________________________________________ Page 10 NTP Experiment-Test: 88034-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC 30-MONTH OZONE Date: 05/08/95 Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 22:21:59 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE MALE CONTROL 0.5 PPM 1.0 PPM ____________________________________________________________________________________________________________________________________ MUSCULOSKELETAL SYSTEM Bone (50) (50) (50) Osteosarcoma 1 (2%) Skeletal Muscle (2) (1) Alveolar/Bronchiolar Carcinoma, Metastatic, Lung 1 (50%) Sarcoma, Metastatic, Seminal Vesicle 1 (50%) Sarcoma, Metastatic, Uncertain Primary Site 1 (100%) ____________________________________________________________________________________________________________________________________ NERVOUS SYSTEM Brain (49) (49) (50) Choristoma 1 (2%) ____________________________________________________________________________________________________________________________________ RESPIRATORY SYSTEM Lung (49) (49) (50) Alveolar/Bronchiolar Adenoma 7 (14%) 8 (16%) 8 (16%) Alveolar/Bronchiolar Adenoma, Multiple 1 (2%) 1 (2%) Alveolar/Bronchiolar Carcinoma 6 (12%) 10 (20%) 14 (28%) Alveolar/Bronchiolar Carcinoma, Multiple 2 (4%) 5 (10%) 4 (8%) Carcinoma, Metastatic, Harderian Gland 2 (4%) 1 (2%) Carcinoma, Metastatic, Salivary Glands 1 (2%) Hepatocellular Carcinoma, Metastatic, Liver 6 (12%) 4 (8%) 7 (14%) Hepatocholangiocarcinoma, Metastatic, Liver 2 (4%) Histiocytic Sarcoma 1 (2%) Osteosarcoma, Metastatic, Bone 1 (2%) Sarcoma, Metastatic, Uncertain Primary Site 1 (2%) Mediastinum, Alveolar/Bronchiolar Carcinoma, Metastatic, Lung 1 (2%) 1 (2%) Mediastinum, Hemangioma 1 (2%) Mediastinum, Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%) Nose (49) (48) (49) Histiocytic Sarcoma 1 (2%) ____________________________________________________________________________________________________________________________________ SPECIAL SENSES SYSTEM Harderian Gland (7) (8) (5) Adenoma 6 (86%) 5 (63%) 4 (80%) Carcinoma 2 (25%) 1 (20%) ____________________________________________________________________________________________________________________________________ Page 11 NTP Experiment-Test: 88034-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC 30-MONTH OZONE Date: 05/08/95 Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 22:21:59 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE MALE CONTROL 0.5 PPM 1.0 PPM ____________________________________________________________________________________________________________________________________ URINARY SYSTEM Kidney (49) (49) (50) Alveolar/Bronchiolar Carcinoma, Metastatic, Lung 1 (2%) Histiocytic Sarcoma 1 (2%) 1 (2%) Urinary Bladder (47) (49) (48) ____________________________________________________________________________________________________________________________________ SYSTEMIC LESIONS Multiple Organs *(50) *(50) *(50) Histiocytic Sarcoma 1 (2%) 1 (2%) 1 (2%) Lymphoma Malignant 2 (4%) 3 (6%) 3 (6%) ____________________________________________________________________________________________________________________________________ * Number of animals with any tissue examined microscopically Page 12 NTP Experiment-Test: 88034-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC 30-MONTH OZONE Date: 05/08/95 Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 22:21:59 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE MALE CONTROL 0.5 PPM 1.0 PPM ____________________________________________________________________________________________________________________________________ TUMOR SUMMARY Total Animals with Primary Neoplasms (b) 43 50 42 Total Primary Neoplasms 78 90 88 Total Animals with Benign Neoplasms 28 32 23 Total Benign Neoplasms 37 37 31 Total Animals with Malignant Neoplasms 30 41 40 Total Malignant Neoplasms 40 53 55 Total Animals with Metastatic Neoplasms 11 7 12 Total Metastatic Neoplasm 25 7 20 Total Animals with Malignant Neoplasms 1 1 Uncertain Primary Site Total Animals with Neoplasms Uncertain- Benign or Malignant 1 1 Total Uncertain Neoplasms 1 2 ____________________________________________________________________________________________________________________________________ a Number of animals examined microscopically at site and number of animals with lesion b Primary tumors: all tumors except metastatic tumors Page 13 ------------------------------------------------------------ ---------- END OF REPORT ---------- ------------------------------------------------------------